Disposition of nasal, intravenous, and oral methadone in healthy volunteers

被引:56
作者
Dale, O [1 ]
Hoffer, C
Sheffels, P
Kharasch, ED
机构
[1] Norwegian Univ Sci & Technol, Dept Anesthesia & Med Imaging, N-7489 Trondheim, Norway
[2] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA
[3] St Olavs Univ Hosp, Dept Anesthesia & Intens Care, Trondheim, Norway
关键词
D O I
10.1067/mcp.2002.128386
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Nasal administration of many opioids demonstrates rapid uptake and fast onset of action. Nasal administration may be an alternative to intravenous and oral administration of methadone and was therefore studied in human volunteers. Methods: The study was approved by the Institutional Review Board of the University of Washington, Seattle. Eight healthy volunteers (6 men and 2 women) aged 19 to 33 years were enrolled after informed written consent was obtained. Subjects received 10 mg methadone hydrochloride nasally, orally, or intravenously on 3 separate occasions in a crossover design. Nasal methadone (50 mg/mL in aqueous solution) was given as a 100-muL spray in each nostril (Pfeiffer BiDose sprayer). Blood samples for liquid chromatography-mass spectrometry analyses of methadone and the metabolite 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium were drawn for up to 96 hours. The methadone effect was measured by noninvasive infrared pupilometry coincident with blood sampling. Results: Nasal uptake of methadone was rapid, with maximum plasma concentrations occurring within 7 minutes. The maximum effects of intravenous, nasal, and oral methadone, on the basis of dark-adapted pupil diameter, were reached in about 15 minutes, 30 minutes, and 2 hours, respectively. The respective durations were 24, 10, and 8 hours. Both nasal and oral bioavailabilities were 0.85. Subjects reported that nasal methadone caused a burning sensation. Conclusions: Nasal administration of methadone results in rapid absorption and onset of effect and high bioavailability, which was greater than that reported for other nasal opioids, with a similar duration of effect. Nasal administration may be an alternative route of methadone administration; however, improved formulations are desirable to reduce nasal irritation.
引用
收藏
页码:536 / 545
页数:10
相关论文
共 60 条
[31]   Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: Clinical observations [J].
Manfredi, PL ;
Borsook, D ;
Chandler, SW ;
Payne, R .
PAIN, 1997, 70 (01) :99-101
[32]   Subcutaneous methadone in terminally ill patients: Manageable local toxicity [J].
Mathew, P ;
Storey, P .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1999, 18 (01) :49-52
[33]   Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home [J].
Mercadante, S ;
Casuccio, A ;
Agnello, A ;
Serretta, R ;
Calderone, L ;
Barresi, L .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (11) :3656-3661
[34]   Methadone response in advanced cancer patients with pain followed at home [J].
Mercadante, S ;
Casuccio, A ;
Agnello, A ;
Barresi, L .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1999, 18 (03) :188-192
[35]   SINGLE DOSE PHARMACOKINETICS AND BIOAVAILABILITY OF METHADONE IN MAN STUDIED WITH A STABLE ISOTOPE METHOD [J].
MERESAAR, U ;
NILSSON, MI ;
HOLMSTRAND, J ;
ANGGARD, E .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 20 (06) :473-478
[36]   METHADONE IN PAIN UNCONTROLLED BY MORPHINE [J].
MORLEY, JS ;
WATT, JWG ;
WELLS, JC ;
MILES, JB ;
FINNEGAN, MJ ;
LENG, G .
LANCET, 1993, 342 (8881) :1243-1243
[37]  
MYGIND N, 1978, STRUCTURE ULTRASTRUC, P3
[38]   CLINICAL PHARMACOKINETICS OF METHADONE [J].
NILSSON, MI ;
MERESAAR, U ;
ANGGARD, E .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1982, 26 :66-69
[39]   A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans [J].
Phimmasone, S ;
Kharasch, ED .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (06) :505-517
[40]   BREAKTHROUGH PAIN - DEFINITION, PREVALENCE AND CHARACTERISTICS [J].
PORTENOY, RK ;
HAGEN, NA .
PAIN, 1990, 41 (03) :273-281